Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS · Delayed Price · Currency is USD

0.0785

0.00 (0.00%)

At close: Jul 6, 2026

63.54% (1Y)

Market Cap	13.64M +1.5%
Revenue (ttm)	n/a
Net Income	-3.35M
EPS	-0.02
Shares Out	173.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,510
Open	0.0785
Previous Close	n/a
Day's Range	0.0785 - 0.0785
52-Week Range	0.0351 - 0.1238
Beta	-0.78
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmace... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1992

Employees 8

Stock Exchange OTCMKTS

Ticker Symbol INTI

Full Company Profile

Financial Performance

Financial Statements

News

Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome

TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program...

3 months ago - GlobeNewsWire

Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.

1 year ago - GlobeNewsWire

Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight

The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria (PN...